ASPCF - Acerus Pharmaceuticals GAAP EPS of -$0.54 revenue of $0.77M November, 15 2022 09:07 AM Acerus Pharmaceuticals Corp Acerus Pharmaceuticals press release ( OTCQB:ASPCF ): Q3 GAAP EPS of -$0.54. Revenue of $0.77M (+30.5% Y/Y). Cash as of September 30, 2022 was $3.0 million compared with $2.2 million as of December 31, 2021 For further details see: Acerus Pharmaceuticals GAAP EPS of -$0.54, revenue of $0.77M